Xspray Pharma AB 2023 AR2
The report highlights Xspray Pharma's progress in 2023, particularly the settlement of its patent dispute with Bristol Myers Squibb regarding Dasynoc®, paving the way for a US launch in September 2024. The company partnered with EVERSANA for US commercialization and raised SEK 251 million through a preferential rights issue. Xspray Pharma also announced a new product candidate, XS008, for kidney cancer and moved to new laboratories in Campus Solna. On the sustainability front, the company focuses on patient safety, responsible procurement, employee diversity, and minimizing environmental impact through its HyNap technology.
Company: Xspray Pharma AB
Sector: Health Care
Country: Sweden
Year: 2023
Type: AR2
Pages: 90
Xspray Pharma AB
Annual Report
The report highlights Xspray Pharma's progress in 2023, particularly the settlement of its patent dispute with Bristol Myers Squibb regarding Dasynoc®, paving the way for a US launch in September 2024. The company partnered with EVERSANA for US commercialization and raised SEK 251 million through a preferential rights issue. Xspray Pharma also announced a new product candidate, XS008, for kidney cancer and moved to new laboratories in Campus Solna. On the sustainability front, the company focuses on patient safety, responsible procurement, employee diversity, and minimizing environmental impact through its HyNap technology.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jan 1, 2023 - Dec 31, 2023
Fiscal Year
2023
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Employees